ImaginAb

ImaginAb is a private, clinical-stage biotechnology company developing targeted in vivo imaging agents based on antibody fragments ('minibodies'). Its lead asset, 89Zr crefmirlimab berdoxam (CD8 ImmunoPET), is in Phase 2 trials for imaging CD8+ T-cells in oncology and has an IND for autoimmune disease. The company operates a platform that generates targeted radiopharmaceuticals for PET and optical imaging, aiming to provide critical biomarkers for immunotherapy development and clinical management. ImaginAb's business model is primarily diagnostic, partnering with pharmaceutical companies and research institutions to accelerate immuno-oncology drug development and patient stratification.

Engineered antibody fragment ('minibody') platform conjugated to radionuclides (e.g., Zirconium-89) or fluorescent dyes for targeted PET and optical imaging of immune cells and other biomarkers.

ImaginAb competes with other companies developing immune-cell imaging tracers, such as those targeting CD8 with peptides or alternative antibody formats, and with standard biopsy-based biomarker approaches. Its differentiated minibody platform offers a balance of target affinity and favorable pharmacokinetics for imaging. It also competes for partnership dollars within the biomarker services sector.